研究者詳細 - 座間味　義人

論文 - 座間味　義人

分割表示 331 件中 21 - 40 件目／全件表示 >>

免疫チェックポイント阻害薬誘発心筋炎の発症予測モデルの構築

山元黎奈, 濱野裕章, 中込昂希, 座間味義人, 上原孝

The Journal of Toxicological Sciences 49 ( Suppl. ) S126 - S127 2024年7月

Effect of Lipopolysaccharide on the Duration of Zolpidem-Induced Loss of Righting Reflex in Mice. 査読

Yudai Wada, Soichiro Ushio, Yoshihisa Kitamura, Yoshito Zamami, Toshiaki Sendo

Acta medica Okayama 78 ( 3 ) 227 - 235 2024年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Zolpidem, a non-benzodiazepine hypnotic, is primarily used to treat insomnia. In a previous study, pior treatment with non-benzodiazepine receptor agonists was associated with inflammation. The present study aimed to clarify the association between the effects of zolpidem and inflammation in mice treated with lipopolysaccharide (LPS), a known model of inflammation. We assessed the zolpidem-induced loss of righting reflex (LORR) duration 24 h after LPS treatment in mice. Additionally, the expressions of γ-aminobutyric acid (GABA)A receptor subunit and K+-Cl- cotransporter isoform 2 (KCC2) mRNA in the hippocampus and frontal cortex were examined in LPS-treated mice. Pretreatment with LPS was associated with significantly prolonged duration of zolpidem-induced LORR compared to control mice. This effect was significantly attenuated by administering bicuculline, a GABAA receptor antagonist, or flumazenil, a benzodiazepine receptor antagonist, in LPS-treated mice. Compared to controls, LPS-treated mice showed no significant change in the expression of GABAA receptor subunits in the hippocampus or frontal cortex. Bumetanide, an Na+-K+-2Cl- cotransporter isoform 1 blocker, attenuated the extended duration of zolpidem-induced LORR observed in LPS-treated mice. LPS significantly decreased Kcc2 mRNA expression in the hippocampus and the frontal cortex. These findings suggest that inflammation increases zolpidem-induced LORR, possibly through a reduction in KCC2 expression.

DOI： 10.18926/AMO/67197

PubMed

researchmap

医薬品供給問題が採用医薬品に与える影響に関する調査後発医薬品の使用促進および代替薬の確保の点から

槇田崇志, 佐田光, 田中雄太, 濱野裕章, 西原茂樹, 村川公央, 座間味義人

ジェネリック研究 ( 第18回学術大会要旨集 ) 65 - 65 2024年5月

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～小児がん治療における探求的アプローチ

岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人

日本臨床腫瘍薬学会雑誌 36 72 - 72 2024年5月

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～小児がん治療における探求的アプローチ

岩田直大, 蔵田靖子, 田中雄太, 濱野裕章, 鍛治園誠, 座間味義人

日本臨床腫瘍薬学会雑誌 36 72 - 72 2024年5月

副作用報告データベースを用いたベバシズマブのバイオシミラーの安全性に関する検討

槇田崇志, 藤井緑, 濱野裕章, 座間味義人

日本医薬品情報学会総会・学術大会講演要旨集 26回 132 - 132 2024年5月

医薬品供給問題が採用医薬品に与える影響に関する調査後発医薬品の使用促進および代替薬の確保の点から

槇田崇志, 佐田光, 田中雄太, 濱野裕章, 西原茂樹, 村川公央, 座間味義人

ジェネリック研究 ( 第18回学術大会要旨集 ) 65 - 65 2024年5月

薬剤師による探索的アプローチの実際～CQからRQへの変換と試験の組み立て方～医療データ解析を起点とした臨床研究の実践

新村貴博, 八木健太, 相澤風花, 石澤有紀, 濱野裕章, 合田光寛, 座間味義人, 石澤啓介

日本臨床腫瘍薬学会雑誌 36 70 - 70 2024年5月

Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. 査読国際誌

Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi

International journal of clinical pharmacy 46 ( 3 ) 745 - 750 2024年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO. METHOD: In total, 40,376 and 38,022 records were extracted from FAERS and VigiBase, and 193 AEs were analysed. The reporting odds ratios (ROR) with 95% confidence interval were calculated using a disproportionality analysis (NIVO-CABO/NIVO-IPI). RESULTS: The reported numbers of immune-related AEs, including myocarditis, colitis, and hepatitis, were significantly higher with NIVO-IPI (ROR = 0.18 for FAERS and 0.13 for VigiBase). Contrarily, the reported numbers of other AEs, including gastrointestinal disorders (ROR = 2.68 and 2.92) and skin and subcutaneous tissue disorders (ROR = 2.94 and 3.55), considered to be potentiated by the combination of NIVO and CABO, were higher with NIVO-CABO. CONCLUSION: Our findings contribute to the selection and clinical management of NIVO-IPI and NIVO-CABO, which minimizes the risk of AEs for individual patients with mRCC by considering distinctive differences in the AE profiles.

DOI： 10.1007/s11096-024-01713-1

PubMed

researchmap

ためになる薬の話薬物相互作用肺癌希少フラクションの分子標的治療薬

奥田浩人, 黒田智, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 1 ) 29 - 32 2024年4月

Burden of depressive disorders in Vietnam from 1990 to 2019: A secondary analysis of the Global Burden of Disease Study 2019. 査読国際誌

Quynh Thi Vu, Ko Harada, Yoshito Nishimura, Hideharu Hagiya, Elizabeth Tan, Odifentse Mapula E Lehasa, Yoshito Zamami, Toshihiro Koyama

Journal of psychiatric research 172 420 - 426 2024年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Depressive disorders are among the leading causes of disability globally. However, information on the burden of depressive disorders in Vietnam is limited. We aimed to analyse the burden of depressive disorders in Vietnam from 1990 to 2019. Using data from the Global Burden of Disease Study 2019, prevalence and disability-adjusted life-years (DALYs) were used as indicators to analyse the burden of depressive disorders by age and sex. In 2019 in Vietnam, depressive disorders comprised 2629.1 thousand (95% uncertainty interval (UI): 2233.3-3155.9) estimated cases and 380.6 thousand (95% UI: 258.9-533.8) estimated DALYs. The crude prevalence rate of depressive disorders was higher among females than among males. The DALYs of depressive disorder accounted for a higher percentage of the total all-cause DALYs in the 10-64-year age group than in other age groups. Major depressive disorder was the largest contributor to the burden of depressive disorders. From 1990 to 2019, the crude prevalence and DALY rates per 100 000 population due to depressive disorders increased significantly, whereas age-standardised rates of prevalence and DALYs decreased significantly; the respective average annual percent changes were 0.88% (95% confidence interval: 0.87 to 0.89), 0.68% (0.66 to 0.70), -0.20% (-0.21 to -0.19), and -0.27% (-0.28 to -0.25). Although the age-standardised prevalence rate was lower than that seen globally, depressive disorders were considerable mental health issues in Vietnam. This study will help governments and policymakers to establish appropriate strategies to reduce the burden of these disorders by identifying the priority areas and individuals.

DOI： 10.1016/j.jpsychires.2024.02.041

PubMed

researchmap

ためになる薬の話薬物相互作用肺癌希少フラクションの分子標的治療薬

奥田浩人, 黒田智, 濱野裕章, 座間味義人

岡山医学会雑誌 136 ( 1 ) 29 - 32 2024年4月

抗がん剤心毒性の統合的な理解～基礎から臨床まで～大規模医療情報データベースを用いた薬剤性心毒性の予防法の開発

濱野裕章, 座間味義人, 牛尾聡一郎, 新村貴博, 合田光寛, 石澤有紀, 石澤啓介

薬学雑誌 144 ( 3 ) 257 - 264 2024年3月

記述言語：日本語出版者・発行元：(公社)日本薬学会

著者らの研究グループでは、薬剤性心毒性への対策を確立することを目標に、大規模な医療情報を活用した研究を行い、医療情報解析によって多数のリスク因子を特定し、それら因子を抑える薬剤について探索している。今回、これまでの研究成果を以下の項目に分けて紹介した。1)医療ビッグデータ解析によって抽出した免疫チェックポイント阻害薬(ICI)関連心筋炎のリスク因子(年齢、性別、薬物相互作用)。2)医療ビッグデータ解析およびオミクスデータベース解析によって抽出したドキソルビシン誘発心毒性における予防候補薬の評価。

researchmap

その他リンク： https://search.jamas.or.jp/default/link?pub_year=2024&ichushi_jid=J01459&link_issn=&doc_id=20240426250003&doc_link_id=%2Fcs7yakug%2F2024%2F014403%2F004%2F0257-0264%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fcs7yakug%2F2024%2F014403%2F004%2F0257-0264%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. 査読国際誌

Tatsuaki Takeda, Shiho Sugimoto, Jun Matsumoto, Naohiro Iwata, Akihiko Nakamoto, Aya Fukuma Ozaki, Hirofumi Hamano, Noritaka Ariyoshi, Yoshito Zamami

International journal of clinical pharmacy 46 ( 2 ) 536 - 541 2024年1月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Palbociclib and abemaciclib are cyclin-dependent kinase (CDK) 4/6 inhibitors currently used to treat breast cancer. Although their therapeutic efficacies are considered comparable, differences in adverse event (AE) profiles of the two drugs remain unclear. AIM: We analysed two real-world databases, the World Health Organization's VigiBase and the Food and Drug Administration Adverse Event Reporting System (FAERS), to identify differences in AE profiles of palbociclib and abemaciclib. METHOD: Data of patients with breast cancer receiving palbociclib or abemaciclib recorded until December 2022 were extracted from the VigiBase and FAERS databases. In total, 200 types of AEs were analysed. The reporting odds ratios were calculated using a disproportionality analysis. RESULTS: Cytopenia was frequently reported in patients receiving palbociclib, whereas interstitial lung disease and diarrhoea were frequently reported in those receiving abemaciclib. Moreover, psychiatric and nervous system disorders were more common in the palbociclib group, whereas renal and urinary disorders were more common in the abemaciclib group. CONCLUSION: This study is the first to show comprehensively the disparities in the AE profiles of palbociclib and abemaciclib. The findings highlight the importance of considering these differences when selecting a suitable CDK4/6 inhibitor to ensure safe and favourable outcomes for patients with breast cancer.

DOI： 10.1007/s11096-023-01687-6

PubMed

researchmap

ステロイドはバンコマイシン関連腎障害を予防するビッグデータ解析・基礎研究・臨床研究の統合による検討

中馬真幸, 合田光寛, 座間味義人, 濱野裕章, 武智研志, 石田俊介, 坂東貴司, 新村貴博, 近藤正輝, 石澤有紀, 田崎嘉一, 石澤啓介

日本臨床薬理学会学術総会抄録集 44回 2 - 2 2024年1月

レセプトデータを用いたダサチニブと胃酸分泌抑制薬の薬物相互作用に関する検討

亀沖真希, 牛尾聡一郎, 佐田光, 建部泰尚, 濱野裕章, 座間味義人

日本臨床薬理学会学術総会抄録集 44回 2 - I3 2024年1月

レセプトデータを用いたダサチニブと胃酸分泌抑制薬の薬物相互作用に関する検討

亀沖真希, 牛尾聡一郎, 佐田光, 建部泰尚, 濱野裕章, 座間味義人

日本臨床薬理学会学術総会抄録集 44回 2 - I3 2024年1月

ステロイドはバンコマイシン関連腎障害を予防するビッグデータ解析・基礎研究・臨床研究の統合による検討

中馬真幸, 合田光寛, 座間味義人, 濱野裕章, 武智研志, 石田俊介, 坂東貴司, 新村貴博, 近藤正輝, 石澤有紀, 田崎嘉一, 石澤啓介

日本臨床薬理学会学術総会抄録集 44回 2 - 2 2024年1月

Lysyl oxidase-like 4 promotes the invasiveness of triple-negative breast cancer cells by orchestrating the invasive machinery formed by annexin A2 and S100A11 on the cell surface. 査読国際誌

Tetta Takahashi, Nahoko Tomonobu, Rie Kinoshita, Ken-Ichi Yamamoto, Hitoshi Murata, Ni Luh Gede Yoni Komalasari, Youyi Chen, Fan Jiang, Yuma Gohara, Toshiki Ochi, I Made Winarsa Ruma, I Wayan Sumardika, Jin Zhou, Tomoko Honjo, Yoshihiko Sakaguchi, Akira Yamauchi, Futoshi Kuribayashi, Eisaku Kondo, Yusuke Inoue, Junichiro Futami, Shinichi Toyooka, Yoshito Zamami, Masakiyo Sakaguchi

Frontiers in oncology 14 1371342 - 1371342 2024年

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Our earlier research revealed that the secreted lysyl oxidase-like 4 (LOXL4) that is highly elevated in triple-negative breast cancer (TNBC) acts as a catalyst to lock annexin A2 on the cell membrane surface, which accelerates invasive outgrowth of the cancer through the binding of integrin-β1 on the cell surface. However, whether this machinery is subject to the LOXL4-mediated intrusive regulation remains uncertain. METHODS: Cell invasion was assessed using a transwell-based assay, protein-protein interactions by an immunoprecipitation-Western blotting technique and immunocytochemistry, and plasmin activity in the cell membrane by gelatin zymography. RESULTS: We revealed that cell surface annexin A2 acts as a receptor of plasminogen via interaction with S100A10, a key cell surface annexin A2-binding factor, and S100A11. We found that the cell surface annexin A2/S100A11 complex leads to mature active plasmin from bound plasminogen, which actively stimulates gelatin digestion, followed by increased invasion. CONCLUSION: We have refined our understanding of the role of LOXL4 in TNBC cell invasion: namely, LOXL4 mediates the upregulation of annexin A2 at the cell surface, the upregulated annexin 2 binds S100A11 and S100A10, and the resulting annexin A2/S100A11 complex acts as a receptor of plasminogen, readily converting it into active-form plasmin and thereby enhancing invasion.

DOI： 10.3389/fonc.2024.1371342

PubMed

researchmap

[Development of Preventive Methods for Drug-induced Cardiotoxicity Using a Large-scale Medical Information Database]. 査読

Hirofumi Hamano, Yoshito Zamami, Soichiro Ushio, Takahiro Niimura, Mitsuhiro Goda, Yuki Izawa-Ishizawa, Keisuke Ishizawa

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 144 ( 3 ) 257 - 264 2024年

記述言語：日本語掲載種別：研究論文（学術雑誌）

Cancer therapies have evolved considerably thereby substantially improving the survival of patients with cancer. However, cardiotoxicity, such as myocarditis and heart failure, induced by anticancer drugs, including immune checkpoint inhibitor(ICI)s and doxorubicin, present serious challenges. Numerous observations have indicated increased risks of cardiotoxicity- and cancer-related mortality in patients with drug-induced cardiotoxicity. Therefore, the prevention and management of drug-induced cardiotoxicity should be prioritized to enable sustainable long-term treatment while preserving patients' quality of life. Recently, medical research has been primarily focused on elucidation of therapeutic benefits and adverse events using medical big data, including worldwide databases of adverse events. The aim of the present study was to establish prevention strategies for drug-induced cardiotoxicity and advance data analytics. A data-driven approach was adopted to comprehensively analyze patient data and drug-induced cardiotoxicity. These data analytics revealed numerous risk factors, leading to the development of drugs that mitigate these factors. Furthermore, many unknown adverse events with molecularly targeted drugs were brought to light. Consequently, the importance of managing adverse events, guided by insights from data science, is predicted to increase. In this symposium review, we introduce our research exemplifying pharmaceutical studies utilizing medical big data. In particular, we discuss in detail the risk factors associated with myocarditis induced by immune checkpoint inhibitors along with prophylactic agents to mitigate doxorubicin-induced cardiotoxicity.

DOI： 10.1248/yakushi.23-00164-2

PubMed

researchmap

　前のページ - 次のページ　

<座間味 義人>

論文 - 座間味 義人

<座間味　義人>

論文 - 座間味　義人